<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02517736</url>
  </required_header>
  <id_info>
    <org_study_id>09-067</org_study_id>
    <nct_id>NCT02517736</nct_id>
  </id_info>
  <brief_title>Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination</brief_title>
  <acronym>O-Mel-Sora</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to determine the efficacy and toxicity of sorafenib in&#xD;
      metastatic uveal melanoma.&#xD;
&#xD;
      The main objective is to determine the non-tumor progression rate 24 weeks after initiation&#xD;
      of treatment with sorafenib at a dose of 800 mg / day&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Actual">January 13, 2015</completion_date>
  <primary_completion_date type="Actual">January 13, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>non-tumor progression rate</measure>
    <time_frame>24 weeks after initiation of treatment</time_frame>
    <description>with sorafenib at a dose of 800 mg / day</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Uveal Melanoma</condition>
  <arm_group>
    <arm_group_label>sorafenib at a dose of 800 mg / day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib at a dose of 800 mg / day</intervention_name>
    <arm_group_label>sorafenib at a dose of 800 mg / day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female over 18 years old suffering from uveal melanoma with metastasis&#xD;
&#xD;
          -  At least one measurable metastases by more than 10 mm acoording to Response Evaluation&#xD;
             Criteria in Solid Tumors (RECIST)&#xD;
&#xD;
          -  At least 28 days from the previous treatment (systemic or major surgery)&#xD;
&#xD;
          -  Performance Index (WHO ≤ 2 or ≥ 70% Karnofsky)&#xD;
&#xD;
          -  Weight loss compared to pre morbid weight &lt;20% in the last 12 months&#xD;
&#xD;
          -  White blood cells at least 3000 / mm 3, polynuclear neutrophils less than 1500 / mm3,&#xD;
             platelets at least 100,000 / mm3, hemoglobin at least 9.0 g / dl&#xD;
&#xD;
          -  Total Bilirubin ≤1.5 x upper limit of normal (ULN) (or less than or equal to 2.5 in&#xD;
             liver metastasis), ASAT and ALAT ≤ 2.5 x ULN (or ≤ 5 in liver metastasis) Serum&#xD;
             Creatinine (calculated using the cockcroft-Gault method) ≤ 1.5 x ULN, Amylase and&#xD;
             lipase &lt;1.5 x ULN&#xD;
&#xD;
          -  prothrombin rate and international normalized ratio (INR) or activated partial&#xD;
             thromboplastin time (aPTT) ≤ 1.5 x ULN. Possibility of using low molecular weight&#xD;
             heparin in place of anti vitamin K treatment&#xD;
&#xD;
          -  higher life expectancy than or equal to 3 months&#xD;
&#xD;
          -  Negative pregnancy test for women of childbearing age and using a method of&#xD;
             contraception during treatment&#xD;
&#xD;
          -  No one benefiting from a Social Security scheme&#xD;
&#xD;
          -  Informed consent and signed by the patient or his legal representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Patient who received more than 2 lines of treatment (chemotherapy or immunotherapy),&#xD;
             whatever the indication&#xD;
&#xD;
               -  Major surgery (excluding the possible diagnostic biopsy) or radiation therapy in&#xD;
                  the 4 weeks preceding the inclusion&#xD;
&#xD;
               -  single liver metastasis treatable by surgery&#xD;
&#xD;
               -  active peptic ulcer, uncontrolled&#xD;
&#xD;
               -  Other progressive malignancy or during treatment (except basal cell carcinoma)&#xD;
&#xD;
               -  Cardiac arrhythmias requiring anti-arrhythmic (excluding beta-blockers or digoxin&#xD;
                  for chronic atrial fibrillation), active or ischemic coronary disease (myocardial&#xD;
                  infarction within the last 6 months), or heart failure&gt; New York Heart&#xD;
                  Association (NYHA) class II&#xD;
&#xD;
               -  Bacterial or fungal infection active (grade&gt; 2 Common Toxicity Criteria for&#xD;
                  Adverse Effects (CTCAE) v4.03)&#xD;
&#xD;
               -  known HIV infection or chronic hepatitis B or C&#xD;
&#xD;
               -  cerebral or meningeal tumor metastasis (symptomatic or asymptomatic)&#xD;
&#xD;
               -  epileptic disease requiring anti-epileptic taken&#xD;
&#xD;
               -  Previous history of organ transplantation or peripheral stem cells&#xD;
&#xD;
               -  Patient kidney dialysis&#xD;
&#xD;
               -  Concomitant treatment with cytochrome P450 3A4 (CYP3A4) inducers such as&#xD;
                  rifampin, St. John's wort, phenytoin, carbamazepine, phenobarbital and&#xD;
                  dexamethasone&#xD;
&#xD;
               -  Prior therapy with bevacizumab or other targeted therapy&#xD;
&#xD;
               -  Known or suspected allergy to sorafenib&#xD;
&#xD;
               -  Any unstable chronic illness can jeopardize patient safety or its compliance&#xD;
&#xD;
               -  Women pregnant or lactating&#xD;
&#xD;
               -  coagulopathy&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Inability to swallow&#xD;
&#xD;
               -  Failure to submit to medical monitoring of the trial due to geographical, social&#xD;
                  or psychic&#xD;
&#xD;
               -  Persons deprived of liberty or under supervision&#xD;
&#xD;
               -  Patient refusing ambulatory care&#xD;
&#xD;
               -  Patient simultaneously participating in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Service d'ophtalmologie, CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>August 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2015</study_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

